Search Result

Results for "

ABT

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) Acyltransferase (1) Adenosine Kinase (2) Amylases (1) Antibiotic (3) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (10) Aurora Kinase (2) Autophagy (7) Bacterial (4) Bcl-2 Family (8) Biochemical Assay Reagents (1) c-Fms (1) c-Kit (1) Calcium Channel (2) Cholinesterase (ChE) (1) COX (1) Cytochrome P450 (1) DNA/RNA Synthesis (2) Dopamine Receptor (2) Drug Metabolite (1) EGFR (3) Endothelin Receptor (3) Farnesyl Transferase (1) Ferroptosis (1) FLT3 (1) HCV (9) HCV Protease (4) Histamine Receptor (1) HIV (7) HIV Protease (7) Interleukin Related (4) Isotope-Labeled Compounds (4) JAK (3) Leukotriene Receptor (1) Ligands for Target Protein for PROTAC (2) Lipoxygenase (1) Microtubule/Tubulin (1) Mitophagy (1) nAChR (14) PARP (3) PDGFR (4) PPAR (1) Proteasome (2) Reactive Oxygen Species (1) SARS-CoV (10) Small Interfering RNA (siRNA) (1) TGF-beta/Smad (1) TNF Receptor (2) TRP Channel (3) VEGFR (5)
By Research Areas:	Cancer (38) Cardiovascular Disease (6) Endocrinology (4) Infection (20) Inflammation/Immunology (23) Metabolic Disease (5) Neurological Disease (24)

By Targets:

11β-HSD (1)

Acyltransferase (1)

Adenosine Kinase (2)

Amylases (1)

Antibiotic (3)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (10)

Aurora Kinase (2)

Autophagy (7)

Bacterial (4)

Bcl-2 Family (8)

Biochemical Assay Reagents (1)

c-Fms (1)

c-Kit (1)

Calcium Channel (2)

Cholinesterase (ChE) (1)

COX (1)

Cytochrome P450 (1)

DNA/RNA Synthesis (2)

Dopamine Receptor (2)

Drug Metabolite (1)

EGFR (3)

Endothelin Receptor (3)

Farnesyl Transferase (1)

Ferroptosis (1)

FLT3 (1)

HCV (9)

HCV Protease (4)

Histamine Receptor (1)

HIV (7)

HIV Protease (7)

Interleukin Related (4)

Isotope-Labeled Compounds (4)

JAK (3)

Leukotriene Receptor (1)

Ligands for Target Protein for PROTAC (2)

Lipoxygenase (1)

Microtubule/Tubulin (1)

Mitophagy (1)

nAChR (14)

PARP (3)

PDGFR (4)

PPAR (1)

Proteasome (2)

Reactive Oxygen Species (1)

SARS-CoV (10)

Small Interfering RNA (siRNA) (1)

TGF-beta/Smad (1)

TNF Receptor (2)

TRP Channel (3)

VEGFR (5)

By Research Areas:

Cancer (38)

Cardiovascular Disease (6)

Endocrinology (4)

Infection (20)

Inflammation/Immunology (23)

Metabolic Disease (5)

Neurological Disease (24)

105

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103389

1-Aminobenzotriazole 4 Publications Verification ABT; 3-Aminobenzotriazole	Cytochrome P450	Cancer
1-Aminobenzotriazole is a nonspecific and irreversible inhibitor of cytochrome P450 (P450).

HY-111262

ABT-384	11β-HSD	Neurological Disease Metabolic Disease
ABT-384 is a potent, selective 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor. ABT-384 exhibits high affinity (K_i 0.1-2.7 nM) against rodent, monkey, and human 11β-HSD1. ABT-384 blocks regeneration of active cortisol. ABT-384 can be used for the research of Alzheimer’s disease (AD) .

HY-112482A

ABT-702 hydrochloride Adenosine Kinase Inhibitor hydrochloride	Adenosine Kinase	Inflammation/Immunology
ABT-702 hydrochloride is a potent inhibitor of adenosine kinase with an IC₅₀ of 1.7 nM .

HY-19881

ABT-288
ABT-288 is a competitive, potent and selective histamine H3 receptor (H3R) antagonist. ABT-288 has K_i values of 1.9 and 8.2 nM for human and rat H3Rs, respectively. ABT-288 can be used in cognitive impairment research. .

HY-10635

ABT-102	TRP Channel	Inflammation/Immunology Cancer
ABT-102 is a potent and highly selective Vanilloid Receptor (TRPV1) receptor antagonist. ABT-102 potently and reversibly increases heat pain thresholds and reduced painfulness of suprathreshold oral/cutaneous heat. ABT-102 reduces nociceptive responses of animals in models of inflammatory, bone cancer, postoperative, and osteoarthritic pain .

HY-105170B

ABT-418 hydrochloride	nAChR	Neurological Disease
ABT-418 hydrochloride is a potent and selective agonist of nAChRs with cognitive enhancing and anxiolytic activities. ABT-418 hydrochloride activates cholinergic channel and can be used for research of Alzheimer's disease .

HY-14330

ABT-724	Dopamine Receptor	Neurological Disease
ABT-724 is a potent and highly selective dopamine D₄ receptor agonist with an EC₅₀ of 12.4 nM for human dopamine D₄ receptor. ABT-724 is a potent partial agonist at the rat D₄ (EC₅₀ of 14.3 nM) and the ferret D₄ receptor (EC₅₀ of 23.2 nM). ABT-724 has no effect on dopamine D₁, D₂, D₃, or D₅ receptors. ABT-724 could be useful for the treatment of erectile dysfunction and has favorable side-effect profile .

HY-108038

ABT-107	nAChR	Neurological Disease
ABT-107 is a selective α7 neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions .

HY-13545

ABT-510	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-13545B

ABT-510 acetate	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-50907

ABT-737 35+ Cited Publications	Bcl-2 Family Apoptosis Autophagy Mitophagy	Cancer
ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-x_L and Bcl-w inhibitor with EC₅₀s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research .

HY-103409

ABT-724 trihydrochloride	Dopamine Receptor	Neurological Disease
ABT-724 trihydrochloride is a potent and highly selective dopamine D₄ receptor agonist with an EC₅₀ of 12.4 nM for human dopamine D₄ receptor. ABT-724 trihydrochloride is a potent partial agonist at the rat D₄ (EC₅₀ of 14.3 nM) and the ferret D₄ receptor (EC₅₀ of 23.2 nM), and has no effect on dopamine D₁, D₂, D₃, or D₅ receptors. ABT-724 trihydrochloride could be useful for the treatment of erectile dysfunction and has favorable side-effect profile .

HY-19569

Upadacitinib 5+ Cited Publications ABT-494	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-113628

ABT-080 VML-530	Leukotriene Receptor	Inflammation/Immunology
ABT-080 is an orally active inhibitor of leukotriene biosynthesis. ABT-080 simultaneously blocks the leukotriene pathways leading to the synthesis of LTB₄ and LTC₄, but does not inhibit PGH2 biosynthesis. ABT-080 can block bronchoconstriction and be used in the research of asthma and related inflammations

HY-19721

ABT-639

2 Publications Verification

Calcium Channel Neurological Disease

ABT-639 is a novel, peripherally acting, selective T-type Ca ²⁺ channel blocker.
HY-103161

ABT-702 dihydrochloride

1 Publications Verification

Adenosine Kinase Inflammation/Immunology

ABT-702 dihydrochloride is a potent adenosine kinase (AK) inhibitor (IC₅₀=1.7 nM).
HY-101616

ABT-639 hydrochloride

Calcium Channel Neurological Disease

ABT-639 hydrochloride is a novel, peripherally acting, selective T-type Ca ²⁺ channel blocker.

ABT-639 2 Publications Verification	Calcium Channel	Neurological Disease
ABT-639 is a novel, peripherally acting, selective T-type Ca ²⁺ channel blocker.

ABT-702 dihydrochloride 1 Publications Verification	Adenosine Kinase	Inflammation/Immunology
ABT-702 dihydrochloride is a potent adenosine kinase (AK) inhibitor (IC₅₀=1.7 nM).

ABT-639 hydrochloride	Calcium Channel	Neurological Disease
ABT-639 hydrochloride is a novel, peripherally acting, selective T-type Ca ²⁺ channel blocker.

HY-119257

ABT-100	Farnesyl Transferase Apoptosis	Cancer
ABT-100 is a potent, highly selective and orally active farnesyltransferase inhibitor. ABT-100 inhibits cell proliferation (IC₅₀s of 2.2 nM, 3.8 nM, 5.9 nM, 6.9 nM, 9.2 nM, 70 nM and 818 nM for EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells, respectively), increases apoptosis and decreases angiogenesis. ABT-100 possesses broad-spectrum antitumor activity .

HY-50907S

ABT-737-d8	Biochemical Assay Reagents	Cancer
ABT 737-d₈ is the deuterium labeled ABT-737. ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-x_L and Bcl-w inhibitor with EC₅₀s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research .

HY-135283

ABT-546 A-216546	Endothelin Receptor	Cardiovascular Disease Endocrinology
ABT-546 (A-216546) is a potent, highly selective and active endothelin ET_A receptor antagonist with a K_i of 0.46 nM for [ ¹²⁵I]endothelin-1 binding to cloned human endothelin ET_A. ABT-546 is >25,000-fold more selective for the ET_A receptor than for the ET_B receptor. ABT-546 blocks endothelin-1-induced arachidonic acid release and phosphatidylinositol hydrolysis with IC₅₀ of 0.59 nM and 3 nM, respectively .

HY-12195

ABT-239 1 Publications Verification	Histamine Receptor TRP Channel	Neurological Disease Endocrinology
ABT-239 is a novel, highly efficacious, non-imidazole class of H3R antagonist and a transient receptor potential vanilloid type 1 (TRPV1) antagonist.

HY-19569R

Upadacitinib (Standard) ABT-494 (Standard)	JAK	Others
Upadacitinib (Standard) is the analytical standard of Upadacitinib. Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-10129

Veliparib

25+ Cited Publications

ABT-888
PARP Autophagy Cancer

Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with K_is of 5.2 and 2.9 nM, respectively .
HY-19483

ABT-670

ABT-670 is a selective, oral bioavailable agonist of dopamine D₄ receptor, with EC₅₀ of 89 nM, 160 nM, and 93 nM for human D₄, ferret D₄, and rat D₄, respectively.

Veliparib 25+ Cited Publications ABT-888	PARP Autophagy	Cancer
Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with K_is of 5.2 and 2.9 nM, respectively .

ABT-670
ABT-670 is a selective, oral bioavailable agonist of dopamine D₄ receptor, with EC₅₀ of 89 nM, 160 nM, and 93 nM for human D₄, ferret D₄, and rat D₄, respectively.

HY-13270

ABT-751 E7010	Microtubule/Tubulin Autophagy Apoptosis	Cancer
ABT-751 (E7010) is a novel, highly orally bioavailable sulfonamides antimitotic compound and tubulin binder. It prevents tubulin aggregation by binding to the colchicine site on β-tubulin, leading to cell cycle arrest in G2/M phase and inducing apoptosis, thus effectively preventing cell division. ABT-751 induces autophagy by inhibiting the AKT/MTOR signaling pathway. ABT-751 showed significant inhibition against various types of cancer cells, including lung, gastric, colon, and breast cancer .

HY-15197

ABT-046	Acyltransferase	Metabolic Disease
ABT-046 is a potent, selective, and orally active acyl CoA:diacylglycerol acyltransferase 1 (DGAT-1) inhibitor with IC₅₀s of both 8 nM against human and mouse DGAT-1 .

HY-19655

Cethromycin

2 Publications Verification

ABT-773; Abbott-195773; A-195773
Bacterial Inflammation/Immunology

Cethromycin (ABT-773) is a ketolide antibiotic .

Cethromycin 2 Publications Verification ABT-773; Abbott-195773; A-195773	Bacterial	Inflammation/Immunology
Cethromycin (ABT-773) is a ketolide antibiotic .

HY-10885

A-620223 succinate ABT-472	PARP	Cancer
A-620223 succinate (ABT-472) is an orally available poly(ADP-ribose) polymerase (PARP) inhibitor. A-620223 succinate (ABT-472) exhibits very good potency against the PARP-1 enzyme with a K_i value of 8 nM and an EC₅₀ value of 3 nM in whole cell assay, making it useful in cancer research .

HY-101634

ABT-072

HCV Infection

ABT-072 is an orally active and potent non-nucleoside HCV NS5B polymerase inhibitor (HCV GT1a EC₅₀=1 nM; HCV GT1b EC₅₀=0.3 nM) .

ABT-072	HCV	Infection
ABT-072 is an orally active and potent non-nucleoside HCV NS5B polymerase inhibitor (HCV GT1a EC₅₀=1 nM; HCV GT1b EC₅₀=0.3 nM) .

HY-117853

Atreleuton ABT-761; VIA-2291	Lipoxygenase	Cardiovascular Disease
Atreleuton (ABT-761) is a selective, reversible, and orally bioavailable 5-Lipoxygenase (5-LO) inhibitor. Atreleuton (ABT-761) exhibits potent and selective inhibition of leukotriene formation . Atreleuton is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14739

Choline Fenofibrate ABT-335	PPAR COX	Cardiovascular Disease
Choline Fenofibrate (ABT-335), a choline salt of Fenofibric acid (HY-B0760), releases free Fenofibric acid in the gastrointestinal tract. Fenofibric acid is a PPAR activator with antihyperlipidemic effect .

HY-109001

Alicapistat 1 Publications Verification ABT-957	Proteasome	Neurological Disease
Alicapistat (ABT-957) is an orally active selective inhibitor of human calpains 1 and 2 for the potential application of Alzheimer's disease (AD) . Alicapistat mitigates the metabolic liability of carbonyl reduction and inhibits calpain 1 with an IC₅₀ value of 395 nM .

HY-14824

Sofiniclin ABT 894	nAChR	Neurological Disease
Sofiniclin (ABT 894), an agonist of nicotinic acetylcholine receptor (nAChR), is used as a potential non-stimulant research for attention-deficit/hyperactivity disorder (ADHD) .

HY-10087

Navitoclax 70+ Cited Publications ABT-263	Bcl-2 Family	Cancer
Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-x_L, Bcl-2 and Bcl-w, with a K_i of less than 1 nM .

HY-16748

Nelonicline ABT-126	nAChR	Neurological Disease
Nelonicline (ABT-126) is an orally active and selective α7 nicotinic receptor agonist with high affinity to α7 nAChRs in human brain (K_i=12.3 nM). Nelonicline is used for the research of shizophrenia and Alzheimer's disease .

HY-101634A

ABT-072 potassium trihydrate	HCV	Infection
ABT-072 (potassium trihydrate) is an orally active and potent non-nucleoside HCV NS5B polymerase inhibitor (HCV GT1a EC₅₀=1 nM; HCV GT1b EC₅₀=0.3 nM) .

HY-P99486

Briakinumab ABT-874	Interleukin Related	Inflammation/Immunology
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .

HY-P99721

Lutikizumab ABT-981	Interleukin Related	Inflammation/Immunology
Lutikizumab (ABT-981) is an anti-IL-1α and IL-1β dual variable domain immunoglobulin. Lutikizumab binds and inhibits IL-1α and IL-1β. Lutikizumab can be used for the research of osteoarthritis .

HY-P99940

Remtolumab ABT-122	TNF Receptor Interleukin Related	Inflammation/Immunology
Remtolumab (ABT-122) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) and IL-17A. Remtolumab shows dual inhibition of TNFα and IL-17A. Remtolumab can be used for rheumatoid arthritis (RA) research .

HY-15403

Atrasentan 5 Publications Verification ABT-627; (+)-A 127722; A-147627	Endothelin Receptor	Cardiovascular Disease Endocrinology Cancer
Atrasentan (ABT-627) is an endothelin receptor antagonist with IC₅₀ of 0.0551 nM for ET_A .

HY-90001

Ritonavir 20+ Cited Publications ABT 538; RTV	HIV Protease HIV SARS-CoV Apoptosis	Infection Cancer
Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.61 μM.

HY-15403A

Atrasentan hydrochloride 5 Publications Verification ABT-627 hydrochloride; (+)-A 127722 hydrochloride; A-147627 hydrochloride	Endothelin Receptor	Cardiovascular Disease Endocrinology Cancer
Atrasentan hydrochloride (ABT-627 hydrochloride) is a selective endothelin A receptor antagonist with an IC₅₀ of 0.0551 nM for ET_A .

HY-16018A

Ilorasertib hydrochloride ABT-348 hydrochloride	Aurora Kinase PDGFR VEGFR	Cancer
Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC₅₀s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .

HY-16018

Ilorasertib ABT-348	Aurora Kinase VEGFR PDGFR	Cancer
Ilorasertib (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC₅₀s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib also is a potent VEGF, PDGF inhibitor. Ilorasertib has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .

HY-13998

Dasabuvir 10+ Cited Publications ABT-333	HCV DNA/RNA Synthesis	Infection
Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively .

HY-13998A

Dasabuvir sodium ABT-333 sodium	HCV DNA/RNA Synthesis	Infection
Dasabuvir (ABT-333) sodium is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir sodium inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir sodium inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively .

HY-44432

Navitoclax-piperazine ABT-263-piperazine	Bcl-2 Family Ligands for Target Protein for PROTAC	Cancer
Navitoclax-piperazine (ABT-263-piperazine) is a B-cell lymphoma extra large (BCL-XL) inhibitor. Navitoclax-piperazine and a VHL ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC DT2216 (HY-130604) .

HY-P99715

Losatuxizumab ABT-806	EGFR	Cancer
Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC₅₀s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFR ^C271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers .

HY-15531

Venetoclax Maximum Cited Publications 123 Publications Verification ABT-199; GDC-0199; RG7601	Bcl-2 Family Autophagy	Cancer
Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a K_i of less than 0.01 nM. Venetoclax induces autophagy .

HY-16748A

Nelonicline citrate ABT-126 citrate	nAChR	Neurological Disease
Nelonicline (ABT-126) citrate is an orally active and selective α7 nicotinic receptor agonist with high affinity to α7 nAChRs in human brain (K_i=12.3 nM). Nelonicline citrate is used for the research of shizophrenia and Alzheimer's disease .

Cat. No.	Product Name	Target	Research Area

HY-13545B

ABT-510 acetate	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-13545

ABT-510	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-P5316

MHLWAAK	Peptides	Inflammation/Immunology
MHLWAAK is an antioxidant active peptide that can be isolated from pancreatin hydrolysate of C-phycocyanin. MHLWAAK has high DPPH and ABTS radical scavenging ability. MHLWAAK protects zebrafish larvae from H₂O₂-induced oxidative damage .

HY-P5316A

MHLWAAK TFA	Peptides	Inflammation/Immunology
MHLWAAK TFA is an antioxidant active peptide that can be isolated from pancreatin hydrolysate of C-phycocyanin. MHLWAAK TFA has high DPPH and ABTS radical scavenging ability. MHLWAAK TFA protects zebrafish larvae from H₂O₂-induced oxidative damage .

HY-P5317

MAQAAEYYR	Peptides	Inflammation/Immunology
MAQAAEYYR is an antioxidant active peptide that can be isolated from pancreatin hydrolysate of C-phycocyanin. MAQAAEYYR has high DPPH and ABTS radical scavenging ability. MAQAAEYYR protects zebrafish larvae from H₂O₂-induced oxidative damage .

HY-P5317A

MAQAAEYYR TFA	Peptides	Inflammation/Immunology
MAQAAEYYR TFA is an antioxidant active peptide that can be isolated from pancreatin hydrolysate of C-phycocyanin. MAQAAEYYR TFA has high DPPH and ABTS radical scavenging ability. MAQAAEYYR TFA protects zebrafish larvae from H₂O₂-induced oxidative damage .

HY-P5318

MDYYFEER	Peptides	Inflammation/Immunology
MDYYFEER is an antioxidant active peptide that can be isolated from pancreatin hydrolysate of C-phycocyanin. MDYYFEER has high DPPH and ABTS radical scavenging ability. MDYYFEER protects zebrafish larvae from H₂O₂-induced oxidative damage .

HY-P5318A

MDYYFEER TFA	Peptides	Inflammation/Immunology
MDYYFEER TFA is an antioxidant active peptide that can be isolated from pancreatin hydrolysate of C-phycocyanin. MDYYFEER TFA has high DPPH and ABTS radical scavenging ability. MDYYFEER TFA protects zebrafish larvae from H₂O₂-induced oxidative damage .

Cat. No.	Product Name	Target	Research Area

HY-P99391

Telisotuzumab ABT-700	Inhibitory Antibodies	Cancer
Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity .

HY-P99486

Briakinumab ABT-874	Interleukin Related	Inflammation/Immunology
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .

HY-P99721

Lutikizumab ABT-981	Interleukin Related	Inflammation/Immunology
Lutikizumab (ABT-981) is an anti-IL-1α and IL-1β dual variable domain immunoglobulin. Lutikizumab binds and inhibits IL-1α and IL-1β. Lutikizumab can be used for the research of osteoarthritis .

HY-P99940

Remtolumab ABT-122	TNF Receptor Interleukin Related	Inflammation/Immunology
Remtolumab (ABT-122) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) and IL-17A. Remtolumab shows dual inhibition of TNFα and IL-17A. Remtolumab can be used for rheumatoid arthritis (RA) research .

HY-P99715

Losatuxizumab ABT-806	EGFR	Cancer
Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC₅₀s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFR ^C271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers .

HY-P99852

Dilpacimab ABT165; PR1283233	VEGFR	Cancer
Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways.. Dilpacimab can be used in research of cancer .

HY-P99359

Elezanumab ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)	TGF-beta/Smad	Metabolic Disease
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC₅₀ around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .

HY-P99496

Cendakimab RPC 4046; ABT 308; CC-93538	Interleukin Related	Inflammation/Immunology
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC₅₀s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .

HY-P99361

Enavatuzumab PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)	TNF Receptor	Cancer
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .

HY-P99849

Depatuxizumab ABT-806	EGFR	Cancer
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N8194

Syringetin-3-O-glucoside Syringetin 3-O-β-D-glucoside	Flavonols Flavonoids Source classification Vitis vinifera cv. Zalema Phenols Polyphenols Plants Vitaceae	Others
Syringetin-3-O-glucosid (Syringetin 3-O-β-D-glucoside), a flavonol glycoside, shows relatively weak DPPH and ABTS radical scavenging activity .

HY-156711

Ternatumoside II	Structural Classification Flavonoids Flavones Source classification Crassulaceae Plants Rhodiola crenulata (HK. f. et.Thoms) H. Ohba	Others
Ternatumoside II is a flavonoid glycoside that can be isolated from R. crenulata. Ternatumoside II can stimulate IFN-γ expression. Ternatumoside II has radical-scavenging activities (IC₅₀s: 260.5 μM and 320.2 μM for DPPH and ABTS) .

HY-N12291

7,4'-Dihydroxyhomoisoflavane	Structural Classification Monophenols Source classification Phenols Plants Asparagaceae Juss.	Others
7,4'-Dihydroxyhomoisoflavane is a natural antioxidant. 7,4'-Dihydroxyhomoisoflavane has ABTS radical-scavenging capacity with an IC₅₀ of 0.22 mg/mL .

HY-N10770

5'-Geranyl-5,7,2',4'-tetrahydroxyflavone	Structural Classification Flavonoids Gramineae Source classification Plants Other Flavonoids Saccharum officinarum	Others
5'-Geranyl-5,7,2',4'-tetrahydroxyflavone, a phenolic compound, presents strong oxygen radical absorbance capacity (ORAC), DPPH radical-scavenging capacity, ABTS radical-scavenging capacity, ferric reducing antioxidant power (FRAP) and nitrite-scavenging capacity. 5'-Geranyl-5,7,2',4'-tetrahydroxyflavone has the potential for natural antioxidant research .

HY-N11997

Feralolide	Structural Classification Liliaceae Source classification Coumarins Phenols Polyphenols Aloe vera (L.) Burm. f. Phenylpropanoids Plants	Cholinesterase (ChE)
Feralolide is a dihydroisocoumarin isolated from the methanolic extract of aloe vera resin. Feralolide is also a dual inhibitor of AChE and BuChE, with IC₅₀s of 55 μg/mL and 52 μg/mL respectively. Feralolide has antioxidant activity and inhibits 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2, 2′-azinobis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS). Feralolide could be used in research into cognitive disorders such as Alzheimer's disease, potentially restoring and enhancing memory .

Cat. No.	Product Name	Chemical Structure

HY-50907S

ABT-737-d8

ABT 737-d₈ is the deuterium labeled ABT-737. ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-x_L and Bcl-w inhibitor with EC₅₀s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research .

HY-W727879

Upadacitinib-15N,d2

Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research .

HY-90001S

Ritonavir-d6
Ritonavir-d₆ is the deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM[1][2].

HY-15531S

Venetoclax-d8
Venetoclax-d₈ is deuterium labeled Venetoclax. Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy[1][2][3].

HY-14814S

Delafloxacin-d5
Delafloxacin-d₅ is deuterium labeled Delafloxacin. Delafloxacin (RX-3341; WQ-3034; ABT492) is a broad-spectrum fluoroquinolone antibiotic. Delafloxacin has a broad spectrum of activity that includes drug-resistant Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumonia[1].

HY-90001S1

Ritonavir-13C,d3
Ritonavir- ¹³C,d₃ is the ¹³C- and deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM.

HY-14588S

(rel)-Lopinavir-d8

(rel)-Lopinavir-d₈ ((rel)-ABT-378-d₈)is the deuterium labeledLopinavir(HY-14588) . Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

HY-90001S3

rel-Ritonavir-d6
rel-Ritonavir-d₆ (rel-ABT 538-d₆; rel-RTV-d₆) is the deuterium labeled Ritonavir (HY-90001). Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.61 μM .

HY-14588S1

Lopinavir-d8
Lopinavir-d₈ (ABT-378-d8) is the deuterium labeled Lopinavir. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity[1][2]. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 μM[3].

HY-10087S

Navitoclax-d8
Navitoclax-d₈ is the deuterium labeled Navitoclax. Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks